Left behind at the Covid vaccine starting line, CureVac files suit against BioNTech over megablockbuster IP claims
BioNTech and their Big Pharma partners at Pfizer handily beat Germany’s CureVac to the market with a megablockbuster mRNA vaccine to fight Covid-19. But CureVac — still working on that front — says their German rival only got there after picking up some of its IP along the way.
And now they want a cut.
CureVac’s first entry in the race to develop an mRNA vaccine floundered in the clinic, missing the bar on efficacy after BioNTech’s rival was already deeply entrenched in the market. Now they say that while they won’t interfere with the sale or distribution of the BioNTech/Pfizer vaccine Comirnaty, they want “fair compensation” for the alleged infringement of a range of their patents.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.